Welcome to our dedicated page for Genprex news (Ticker: GNPX), a resource for investors and traders seeking the latest updates and insights on Genprex stock.
Genprex, Inc. (NASDAQ: GNPX) is a pioneering clinical-stage gene therapy company committed to transforming the landscape of cancer and diabetes treatments. The company's mission is to address the unmet medical needs of a growing population of patients worldwide through the development of innovative immunogene therapies. Genprex's flagship product, Reqorsa Immunogene Therapy (quaratusugene ozeplasmid), is at the forefront of its oncology program and is currently being evaluated in three clinical trials targeting non-small cell lung cancer (NSCLC) and small cell lung cancer (SCLC).
Oncoprex® Delivery System, Genprex's proprietary platform, encapsulates gene-expressing plasmids using lipid-based nanoparticles. This systemic, non-viral method enables the intravenous delivery of tumor suppressor genes to cancer cells, which then express proteins that were deficient in the tumor. Reqorsa Immunogene Therapy has shown promise by re-establishing pathways for programmed cell death, interrupting cancer cell signaling, and modulating immune responses.
The company's recent achievements include securing new patents and receiving FDA Fast Track and Orphan Drug designations for its clinical programs. Specifically, the Acclaim-2 and Acclaim-3 studies are exploring the potential of Reqorsa in combination with immune checkpoint inhibitors like Keytruda® and Tecentriq®. These trials aim to provide new therapeutic options for patients with advanced-stage lung cancers who have limited treatment alternatives.
In addition to its oncology initiatives, Genprex is advancing a novel gene therapy approach for diabetes. Using an AAV vector, the company delivers Pdx1 and MafA genes directly to the pancreas to transform alpha cells into beta-like cells capable of producing insulin. This method shows promise for both Type 1 and Type 2 diabetes and aims to offer a new lifeline for patients with these conditions.
Genprex collaborates with renowned institutions and industry leaders to further its research and development pipeline. The company's commitment to innovation and patient-centric solutions positions it as a significant player in the gene therapy landscape.
Latest News:
- March 12, 2024 - Genprex announces new patent grants in South Korea for Reqorsa® Immunogene Therapy.
- March 19, 2024 - Genprex enters into agreements for the sale and issuance of shares, expecting gross proceeds of $6.5 million.
- April 2, 2024 - Positive preclinical data for NPRL2 gene therapy presented at AACR Annual Meeting.
- April 3, 2024 - Multiple new trial sites added for Acclaim-3 study in extensive-stage small cell lung cancer.
- April 9, 2024 - Research collaborators present positive preclinical data supporting Reqorsa and NPRL2 therapies.
- May 8, 2024 - Genprex announces the passing of its co-founder and CEO Rodney Varner.
- May 14, 2024 - First patient dosed in Phase 1 of Acclaim-3 clinical study for Reqorsa® and Tecentriq® combination therapy.
Genprex, Inc. (GNPX) announced positive preclinical data on NPRL2 gene therapy at the AACR 2023 annual meeting, demonstrating effective anti-tumor activity against non-small cell lung cancer (NSCLC) resistant to pembrolizumab using their ONCOPREX® delivery system. This research, conducted in a humanized mouse model, showcases the potential of NPRL2 as a new drug candidate for NSCLC. The study highlights that NPRL2 therapy significantly improved anti-tumor immune responses compared to pembrolizumab alone. Genprex's ONCOPREX® system effectively delivers tumor suppressor genes intravenously, potentially positioning the company to expand its oncology pipeline. Current clinical trials include REQORSA® in combination with Tagrisso® and Keytruda® for late-stage NSCLC, with promising outcomes paving the way for future therapeutic developments.
Genprex, Inc. (NASDAQ: GNPX) announced pre-clinical findings revealing that the tumor suppressor gene TUSC2 significantly inhibits glioblastoma. Independent researchers presented these results at the 2023 American Association for Cancer Research Annual Meeting. The study showed that TUSC2 overexpression decreases colony and neurosphere formation, induces apoptosis in glioblastoma cells in vitro, and suppresses tumor growth in vivo. Additionally, the research found that TUSC2 protein levels were significantly lower in glioblastoma compared to normal brain tissue. The study supports ongoing investigations into TUSC2 as a potential target for various cancers, enhancing the therapeutic potential of Genprex's lead drug candidate, REQORSA®, which is currently being evaluated for non-small cell lung cancer and small cell lung cancer.
Genprex (GNPX), a clinical-stage gene therapy company, announced its support for the FDA's initiative aimed at expediting gene therapy development for rare diseases. The FDA's new approach will allow biomarkers to substitute for traditional biological indicators in clinical trials, potentially accelerating approval processes. Rodney Varner, CEO, emphasized that this initiative is beneficial for advancing Genprex's pipeline of gene therapies, particularly for patients with limited treatment options in cancer and diabetes. The company is utilizing its proprietary ONCOPREX Nanoparticle Delivery System for its oncology program, currently in clinical trials.
Genprex (NASDAQ: GNPX), a clinical-stage gene therapy company, announces that Dr. Hemant Kumar, Chief Manufacturing and Technology Officer, will speak at the Bioprocessing Summit Europe in Barcelona, Spain from March 14-16, 2023. His presentation titled Managing Headwinds Due to CDMO's M&A Activities will discuss how recent mergers and acquisitions in the Contract Development and Manufacturing Organization (CDMO) sector affect gene therapy innovations. Dr. Kumar emphasizes the need for partnerships to navigate increased costs and regulatory delays, highlighting Genprex's commitment to developing life-changing therapies for cancer and diabetes. More details can be found at www.genprex.com.
Genprex, a clinical-stage gene therapy company focusing on treatments for cancer and diabetes, has announced its participation in two major conferences in March 2023. The Roth Conference will occur from March 12-14 in Laguna Niguel, California, and the BIO-Europe Spring will take place from March 20-22 in Basel, Switzerland. CFO Ryan Confer will represent Genprex at the Roth Conference, while multiple executives will attend BIO-Europe Spring. CEO Rodney Varner expressed enthusiasm about showcasing their innovative gene therapies, including updates on the REQORSA clinical trial for lung cancer and data on therapies for Type 1 diabetes.
Genprex, Inc. (NASDAQ: GNPX) announced a registered direct offering with a healthcare-focused institutional investor, involving 3,809,524 shares and warrants priced at $1.05 per share. The warrants will have an exercise price of $1.10 and expire in five years. The offering, expected to close on or about March 1, 2023, will generate approximately $4 million in gross proceeds, earmarked for general working capital. A.G.P./Alliance Global Partners acts as the sole placement agent. This transaction is conducted under an existing shelf registration statement filed with the SEC.
FAQ
What is the current stock price of Genprex (GNPX)?
What is the market cap of Genprex (GNPX)?
What is Genprex's main focus?
What is Reqorsa Immunogene Therapy?
How does the Oncoprex® Delivery System work?
What recent achievements has Genprex made?
What is the status of Genprex's clinical trials?
What are the implications of Genprex's recent patent grants?
What is Genprex's approach to diabetes treatment?
How does Reqorsa enhance current cancer treatments?
Who are Genprex's key collaborators?
How has Genprex adapted to recent leadership changes?
